[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648611":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":34,"responsibleParty":51,"collaborators":11,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Mirati Therapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adagrasib","EXPERIMENTAL",null,[13],"Drug: Adagrasib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Specified dose on specified days",[9],[20,21],"BMS-986503","MRTX849",[23],{"name":24,"affiliation":24,"role":25},"Bristol-Myers Squibb","STUDY_DIRECTOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":33,"role":29,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[35],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Local Institution - 0001","Anaheim","California","92801","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-117.9145,33.83529,{"lat":46,"lon":45},[49],{"name":50,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0001",{"type":52,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100648611","phase-1-a-study-to-assess-the-pharmacokinetics-safety-and-tolerability-of-single-dose-adagrasib-bms-986503-in-healthy-participants-of-japanese-descent-100648611",false,"NCT07723118","A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent","A Phase 1, Single-dose, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent","Inclusion Criteria:\n\n* Participants must be of Japanese descent (both biological parents of the participant are ethnically Japanese).\n* Participants must be healthy adult without clinically significant deviation from normal in medical history, PE, 12-lead ECG, vital sign measurements, and clinical laboratory assessments as determined by the investigator.\n* Participants must have Body mass index of 18.0 kg\u002Fm2 to 32.0 kg\u002Fm2.\n* Participants must have Total body weight ≥ 50 kg.\n\nExclusion Criteria:\n\n* Participants must not have significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator.\n* Other protocol defined Inclusion\u002FExclusion criteria apply.",true,"ALL","18 Years","60 Years",{"count":65,"type":66},10,"ESTIMATED","INTERVENTIONAL",[69],"PHASE1","The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent",[72],"Healthy Participants",[74,75],"Japanese Descent","Phase 1","NOT_YET_RECRUITING","2026-07-20",{"date":79,"type":80},"2026-07-23","ACTUAL",{"date":82,"type":66},"2026-08-05",{"date":84,"type":66},"2026-09-12",{"name":5,"class":6},1]